Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ADA | P00813 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.42 |
| ▸ | ADK | P55263 | 2/20 | 0.42 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.42 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | ROS1 | P08922 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28642522 | 1.00 | PNP (0.52) | PNPKDM4EADAMEN1KMT2A | |
| SCHEMBL460189 | 0.86 | PNP (0.67) | PNPKDM4EADAMEN1KMT2A | |
| SCHEMBL7057522 | 0.86 | PNP (0.67) | PNPKDM4EADAMEN1KMT2A | |
| SCHEMBL1100799 | 0.86 | PNP (0.67) | PNPKDM4EADAMEN1KMT2A | |
| SCHEMBL28603432 | 0.83 | PNP (0.52) | PNPKDM4EADAMEN1KMT2A | |
| Thioguanosine SCHEMBL14156817 | 0.78 | LMNA (0.62) | MEN1KMT2ASMN1; SMN2LMNADOT1L | |
| Thioguanosine SCHEMBL4527562 | 0.78 | LMNA (0.62) | MEN1KMT2ASMN1; SMN2LMNADOT1L | |
| Thioguanosine SCHEMBL2619736 | 0.78 | LMNA (0.62) | MEN1KMT2ASMN1; SMN2LMNADOT1L | |
| SCHEMBL9149290 | 0.78 | PNP (0.59) | PNPMEN1KMT2ACYP3A4MAPT | |
| Thioguanosine SCHEMBL230740 | 0.78 | LMNA (0.62) | MEN1KMT2ASMN1; SMN2LMNADOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2558 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4393484-A1 | COMPOSITION FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACID | Themedium Therapeutics Co., Ltd. (CN) | 2024-07-03 | — | — | EP | claimed |
| EP-4393511-A1 | LIPID COMPOUND AND USE THEREOF | Themedium Therapeutics Co., Ltd. (CN) | 2024-07-03 | — | — | EP | claimed |
| WO-2024129779-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| US-20240200118-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2024-06-20 | — | — | US | claimed |
| WO-2024123812-A1 | FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES | SHATTUCK LABS, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| EP-4379052-A2 | MRNA PURIFICATION BY TANGENTIAL FLOW FILTRATION | Ethris GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| WO-2024097875-A1 | FUSION PROTEINS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS | SHATTUCK LABS, INC. (US) | 2024-05-10 | — | — | WO | claimed |
| EP-4324473-A2 | MULTIPARAMETRIC NUCLEIC ACID OPTIMIZATION | ModernaTX, Inc. (US) | 2024-02-21 | — | — | EP | claimed |
| WO-2024031087-A2 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-02-08 | — | — | WO | claimed |
| CN-117500823-A | Chimeric proteins in autoimmunity | 沙塔克实验室有限公司 | 2024-02-02 | — | — | CN | claimed |
| EP-2691101-A2 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | Moderna Therapeutics, Inc. (US) | 2014-02-05 | — | — | EP | claimed |
| WO-2013151672-A2 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | modeRNA Therapeutics (US) | 2013-10-10 | — | — | WO | claimed |
| WO-2013151671-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF COSMETIC PROTEINS AND PEPTIDES | modeRNA Therapeutics (US) | 2013-10-10 | — | — | WO | claimed |
| WO-2013151736-A2 | IN VIVO PRODUCTION OF PROTEINS | modeRNA Therapeutics (US) | 2013-10-10 | — | — | WO | claimed |
| WO-2013086008-A1 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | FACTOR BIOSCIENCE INC. (US) | 2013-06-13 | — | — | WO | claimed |
| WO-2013039861-A2 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF | modeRNA Therapeutics (US) | 2013-03-21 | — | — | WO | claimed |
| WO-2013039857-A1 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF | modeRNA Therapeutics (US) | 2013-03-21 | — | — | WO | claimed |
| WO-2012158736-A1 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF FOR NON-HUMAN VERTEBRATES | modeRNA Therapeutics (US) | 2012-11-22 | — | — | WO | claimed |
| US-20120251618-A1 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | modeRNA Therapeutics (US) | 2012-10-04 | — | — | US | claimed |
| WO-2012135805-A2 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | modeRNA Therapeutics (US) | 2012-10-04 | — | — | WO | claimed |